Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers.
Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, Kruithof I, Zhang GJ, Robinson DJ, Nagengast WB, Jorritsma-Smit A, van der Vegt B, van Dam GM. Nat Commun. 2018 Sep 18;9(1):3739. doi: 10.1038/s41467-018-05727-y. PubMed PMID: 30228269; PubMed Central PMCID: PMC6143516.
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder
CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries
EGE, Ntziachristos V, van Dam GM. Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi:10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9. PubMed PMID: 28119364.
